- Home
- XPO vs ROIV Comparison
XPO vs ROIV Comparison
Compare XPO & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XPO | ROIV |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.2B | 20.7B |
| IPO Year | 2002 | 2021 |
Fundamental Metrics
Financial Performance| Metric | XPO | ROIV |
|---|---|---|
| Price | $187.36 | $27.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 8 |
| Target Price | ★ $171.59 | $27.56 |
| AVG Volume (30 Days) | 1.3M | ★ 4.6M |
| Earning Date | 04-29-2026 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.64 | N/A |
| Revenue | ★ $7,744,000,000.00 | $29,053,000.00 |
| Revenue This Year | $5.39 | N/A |
| Revenue Next Year | $6.56 | $594.84 |
| P/E Ratio | $71.95 | ★ N/A |
| Revenue Growth | ★ 0.34 | N/A |
| 52 Week Low | $85.06 | $8.73 |
| 52 Week High | $220.50 | $30.33 |
Technical Indicators
Market Signals| Indicator | XPO | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 47.00 | 50.92 |
| Support Level | $122.62 | $26.94 |
| Resistance Level | $207.04 | $27.94 |
| Average True Range (ATR) | 8.34 | 0.96 |
| MACD | -3.17 | -0.36 |
| Stochastic Oscillator | 18.69 | 23.85 |
Price Performance
Historical ComparisonAbout XPO XPO Inc.
Following the spinoff of its contract logistics division (GXO) in 2021 and freight brokerage operations (RXO) in 2022, XPO is moving closer to becoming a pure-play asset-based less-than-truckload carrier. We estimate LTL shipping makes up 60% of total revenue, with XPO's European truckload and LTL operations making up 40%. However, XPO's LTL segment EBITDA mix is much higher than 60%. We believe XPO intends to divest its European trucking division once it finds the right buyer.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.